share_log

Cantor Fitzgerald Reiterates Overweight on ADMA Biologics, Maintains $20 Price Target

Benzinga ·  Sep 20, 2024 23:10  · Ratings

Cantor Fitzgerald analyst Kristen Kluska reiterates ADMA Biologics (NASDAQ:ADMA) with a Overweight and maintains $20 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment